Pomerantz LLP is investigating Iovance Biotherapeutics for potential securities fraud following a revision in its Phase 2 lung cancer trial results. Initially reported as "Positive," the data was later described as "Consistent with Previously Reported Results," revealing a subgroup response rate lower than standard treatment. This led to a 35.45% drop in Iovance's stock price. The investigation will determine if the company or its executives engaged in unlawful practices affecting investors.
As of Nov 11, 2026 04:52 WIB, Iovance Biotherapeutics (IOVA) is trading at USD 8.08 on Pluang, down 1.10% for the day. The stock shows a market cap of $3.78 billion with a volume of 13,674,203 shares. Notably, Pluang order activity leans towards selling at 59%, indicating cautious sentiment among investors.
David H. Lerner focuses on long-term biotech investments using technical analysis, emphasizing price action and volume rather than traditional fundamentals. He targets small-cap biotech companies advancing beyond Phase 2 trials, especially those deve...
Iovance Biotherapeutics reported a strong Q3 with revenues up about 80% year-over-year and a gross margin of 60%. The company reaffirmed its 2026 revenue guidance of $410–$420 million and holds a solid cash reserve of $376 million, expected to last u...
Iovance Biotherapeutics' stock fell 46% following a downgrade to Hold due to over-optimism in its valuation. While the melanoma drug AMTAGVI (lifileucel) is gaining market traction, the potential for its use in non-small cell lung cancer (NSCLC) appe...
